Grand Pharma Reaches Strategic Cooperation with Eye Hospital, WMU, Strategically Planning the New Ophthalmic Preparation, And Building Public Eye Protection Ecosystem 2022-5-25 Corporate News READ MORE
Grand Pharma’s Global Innovative Product STC3141 Approved for Phase Ib Clinical Study in Belgium, Another Milestone of Global Innovative Products and Continues the Globalization Development Process 2022-4-26 Corporate News READ MORE
The Phase III Clinical Trial in China of Grand Pharma’s Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment, Milestone Progress in the Landing Process of Innovative Products and Continuously Consolidating Core Competitiveness in Pharmaceutical Industry 2022-4-7 Corporate News READ MORE
Grand Pharma Announces 2021 Annual Results, Profit Attributable to Owners of the Company Increase 34.0% to HK$2,402.6 million, Continuing to Deepen the Strategic Plan of Global Technological Innovation, Multiple Products will be Lunched Successively to Provide Long-term Momentum 2022-3-18 Corporate News READ MORE
Grand Pharma Entered into an Equity Investment Agreement with ITM in Germany, Further Consolidate the Group’s Comprehensive Industrial Chain Layout in Research, Production and Commercialization of Radionuclides 2022-2-16 Corporate News READ MORE
Grand Pharma’s Global Innovative Radiopharmaceutical Drugs SIR-Spheres® Y-90 Microsphere Injection Were Approved for Commercialization by NMPA in China, For The Treatment of Colorectal Cancer Liver Metastases 2022-2-9 Corporate News READ MORE
GP (HK) Entered into an Exclusive Product Licensing Agreement with ITM in Germany, Strategically Plans Three Global Innovative RDC Drugs, Significant Milestone in the Field of Radionuclide Drugs 2021-12-27 Corporate News READ MORE
GP (HK)’s Global Innovative RDC Drug TLX591-CDX Was Approved in The United States, Another Milestone Progress of the Group’s Innovative Products’ Commercialization 2021-12-21 Corporate News READ MORE
GP (HK)’s Global Innovative Drug STC3141 Successfully Completed the Enrolment and Dosing of All Patients in Phase IIa Clinical Trial for COVID-19 in Europe, Another Milestone in Global Clinical Trial, and Consolidating the Strategic Plan in the Field of Severe Anti-infection 2021-12-14 Corporate News READ MORE
GP (HK) Introduces A Global Innovative Mitral Valve Replacement Medical Device – Saturn, Continue To Deepen The Product Pipeline Strategic Plan In The Field Of Precision Interventional Diagnosis And Treatment 2021-11-28 Corporate News READ MORE
GP (HK)’s Global Innovative Drug STC3141 Successfully Dosed the First Patient of its Phase Ib Clinical Trial for ARDS In China, Deepen the Dual-Cycle Development Strategy and Continues the Global Development Process 2021-11-10 Corporate News READ MORE
GP (HK)’s Global Innovative Drug Ryaltris Compound Nasal Spray Has Been Granted Phase Three Clinical Trial Approval, Enriches the Group’s Product Pipeline, and Consolidates its Competitive Advantage in the field of Respiratory & ENT 2021-10-21 Corporate News READ MORE
English
